DEBORAH EVANS: Open Payments
NPI 1891103073 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,172 in 56 payments from 13 companies in 2025. Trend: 2023 $912 · 2024 $1,167 · 2025 $1,172
Food & beverage: $1,172
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $176 |
| Actelion Pharmaceuticals US, Inc. | 13 | $176 |
| Novo Nordisk Inc | 4 | $160 |
| Novartis Pharmaceuticals Corporation | 11 | $148 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $139 |
| Alnylam Pharmaceuticals Inc. | 5 | $84 |
| BridgeBio Pharma, Inc. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| United Therapeutics Corporation | 3 | $48 |
| Kestra Medical Technology Services, Inc. | 1 | $41 |
Products named: JARDIANCE, LEQVIO, Ozempic, Kerendia, UPTRAVI, AMVUTTRA, OPSUMIT, Attruby.
Industry payments across AR — which companies pay providers there.
